GvHD is an acquired immune disorder caused by the recognition of host tissue antigens by donor-derived T cells following allogeneic hematopoietic stem cell transplantation. No causal genes or inheritance patterns are recorded in this packet, consistent with the condition's acquired rather than germline etiology.

Diagnostic criteria and evaluation protocols are not detailed in this packet. Clinical presentation, histopathologic assessment of affected tissues, and transplant history inform the diagnostic process, though specifics are outside the scope of packet data available here.

Two FDA-approved treatments with active market status are documented in this packet as applicable to GvHD. Ruxolitinib (JAKAFI), a JAK1/JAK2 inhibitor available as an oral formulation, received NDA approval in November 2011 and holds indications for both steroid-refractory acute and chronic GvHD. Abatacept (ORENCIA), a CTLA-4 immunoglobulin fusion protein, received BLA approval in December 2005 and is listed in this packet as an approved agent. The packet records 179 active clinical trials for this disease, indicating extensive ongoing research into additional therapeutic approaches.

Prognostic information is not itemized in this packet. Outcomes vary by GvHD severity, organ involvement, and response to initial treatment; these variables are not characterized in the current packet data.

The packet records 179 active clinical trials for graft versus host disease, among the highest trial volumes for any disease in this series. The ten listed trial details span Phase 2 through Phase 4 and include studies of ruxolitinib in steroid-refractory acute GvHD, ocular chronic GvHD interventions, and multiple cellular therapy approaches. Orphan drug designations have been granted for numerous investigational agents in this space, including belumosudil (Rezurock), emapalumab, and several mesenchymal stromal cell-based products.